CNP-104

Chemomab Therapeutics has secured FDA alignment for a streamlined phase 3 registration study of nebokitug (CM-101) in primary sclerosing cholangitis, marking a significant advancement in treatment development.

COUR Pharmaceuticals' CNP-104, a novel therapy for primary biliary cholangitis (PBC), has been granted Orphan Drug Designation by the FDA.

CNP-104 demonstrated a statistically significant decrease in liver stiffness compared to placebo in patients with primary biliary cholangitis (PBC).

From 2000 to 2021, the US saw a significant increase in primary liver cancer cases and deaths, primarily due to Alcohol-Associated Liver Disease (ALD) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).